Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.00.
A number of equities analysts recently weighed in on the stock. Citigroup lowered their price target on shares of Adaptimmune Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 7th. Mizuho boosted their price target on shares of Adaptimmune Therapeutics from $3.00 to $9.00 and gave the stock a “neutral” rating in a report on Monday, June 1st. Finally, SVB Leerink reiterated a “market perform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, May 14th.
In other Adaptimmune Therapeutics news, Director James Noble sold 500,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $9.33, for a total transaction of $4,665,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gavin Wood acquired 33,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were purchased at an average price of $1.62 per share, with a total value of $53,460.00. Following the transaction, the chief financial officer now owns 33,000 shares in the company, valued at approximately $53,460. The disclosure for this purchase can be found here. 18.89% of the stock is currently owned by corporate insiders.
Shares of NASDAQ ADAP traded up $0.35 during mid-day trading on Tuesday, hitting $9.35. 699,198 shares of the company’s stock traded hands, compared to its average volume of 803,719. The company’s 50-day moving average is $9.43 and its two-hundred day moving average is $5.63. The company has a market capitalization of $1.22 billion, a P/E ratio of -7.14 and a beta of 2.41. Adaptimmune Therapeutics has a 1 year low of $0.71 and a 1 year high of $13.40.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative net margin of 7,324.48% and a negative return on equity of 85.62%. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $25.90 million. On average, equities analysts expect that Adaptimmune Therapeutics will post -0.97 EPS for the current fiscal year.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: Do stock splits help investors?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.